MAY 11, 2016 02:07 PM PDT

Pathogen-specific antibiotics protect gut bacteria

WRITTEN BY: Kerry Evans
You take antibiotics for an infection, right? Broad-spectrum antibiotics kill the harmful bacteria, yes. The problem is that they also kill your beneficial gut microbes - those guys that help you digest food and provide vitamins.

Researchers at St. Jude Children’s Research Hospital demonstrated that a Staphylococcus aureus-specific antibiotic called Debio 1452 (produced by Debiopharm International) effectively spared much of the gut microbiome when given orally to mice.
 
Broad-spectrum antibiotics damage the microbiome.

According to study author Charles Rock, “in this study, we demonstrated that the pathogen-selective approach to antibiotic development is an effective way to minimize collateral damage to beneficial bacteria in the gut microbiome. Such treatment strategies will become increasingly important for use in antibiotic drug design thanks to the growing awareness of the vital role that the gut microbiome plays in digestion and immune protection.”

The antibiotic works by blocking the activity of an enzyme called FabI. Staph needs this enzyme to grow, but most other bacteria do not.

The group compared the effect of Debio 1452 and broad-spectrum antibiotics (linezolid, clindamycin, amoxicillin, of moxifloxacin) on the gut bacteria of mice. They used next-generation sequencing techniques to identify and quantify bacteria from stool samples.

The broad-spectrum antibiotics decreased the abundance of gut microbes up to 4,000 fold! (That’s a lot.) Debio 1452, on the other hand, had little effect. What’s more, the concentration of Debio in mice was 12 times higher than what would be given to humans!

Broad-spectrum antibiotics also decreased the diversity of gut bacteria, but Debio 1452 altered diversity very little. Interestingly, the quantity of bacteria depleted with the broad-spectrum antibiotics returned to normal within a week, but diversity remained skewed.

This pathogen-specific approach does have an obvious drawback, however. It requires researchers to identify factors - enzymes, for example - that are essential to each pathogen and design a drug to specifically target that weakness.

Sources: Antimicrobial Agents and Chemotherapy, Alpha Galileo
About the Author
  • Kerry received a doctorate in microbiology from the University of Arkansas for Medical Sciences.
You May Also Like
SEP 22, 2018
Videos
SEP 22, 2018
Did a Vampire Facial Expose Patients to Bloodborne Disease?
It seems there is no shortage of unusual beauty rituals; vampire facials may fall into that category....
SEP 30, 2018
Drug Discovery
SEP 30, 2018
Researchers Re-classify the 'Magic Mushroom' Drug
Researchers at John Hopkins have evaluated the safety and efficacy of compound, psilocybin, found in hallucinogenic mushrooms. They suggested that if evalu...
OCT 21, 2018
Microbiology
OCT 21, 2018
The Evolution and Spread of Drug-resistant Tuberculosis
Once thought to have come from Africa ~5,000 years ago, the dominant form of this pathogen really came from Europe, and colonialists spread it around the globe....
NOV 06, 2018
Microbiology
NOV 06, 2018
A Move to the US Significantly Changes a Person's Microbiome
A move to the United States is extremely disruptive to health of a person's gut microbial community, researchers have found....
NOV 12, 2018
Microbiology
NOV 12, 2018
Some Bacteria Gain Resistance Even Without Exposure to Antibiotics
Most bacteria are harmless, some are even beneficial to us. But some of the dangerous ones pose a real threat to public health....
DEC 08, 2018
Cardiology
DEC 08, 2018
Atrial Fibrillation, Explained
Atrial fibrillation (A-Fib) is a term you've likely heard before. You may have even been told you live with A-Fib. What exactly is this common type of...
Loading Comments...